265

Last update : 10/20/2017

EXACO - Cohort of Patients with Chronic Obstructive Pulmonary Disease

Head : Masure Frédéric
Cortot Alexis
Schuck Stephane

Version 1

266

Last update : 01/01/2020

EXACO - Cohort of Patients with Chronic Obstructive Pulmonary Disease

Head : Masure Frédéric
Cortot Alexis
Schuck Stephane

Main objective

The main aims of the study are to qualitatively and quantitatively describe the exacerbations in a cohort of COPD patients at different levels of severity and to confirm the existence of a sub-group of patients defined as frequent exacerbators who experience a high number of exacerbations over time.
Where applicable, to determine the threshold value (number of exacerbations) that distinguishes frequent exacerbations by assuming that 3 exacerbations per year, regardless of severity, are sufficient to class the patient as a “frequent” exacerbator.

Several secondary aims will also be pursued.
To identify factors associated with frequent exacerbators.
To identify criteria more readily associated with exacerbation severity.
To confirm the link between frequent exacerbators/accelerated decline in lung function.
A validation of the VSRQ scale will be performed with the following metrics: replication; clinical validity through comparison with the St. George questionnaire; VSRQ unidimensional structure; VSRQ internal consistency; sensitivity to change; minimal important distance.

Inclusion criteria

Respiratory physicians (private practice or hospital: CHG, CHU) will enrol patients aged 40 and over with stage II or III COPD according to SPLF criteria (2003); smokers or ex-smokers (>15 pack-years); stable and with post-bronchodilator FEV1 lower than or equal to 80% of predicted value and FEV1/VC relationship <70%. Patients must accept and complete the self-monitoring log on a monthly basis and, at each exacerbation, can be contacted by phone every three months for 4 years. Participants shall sign a consent form.

The following may not be included: patients with active tuberculosis, cancer (or who received cancer treatment in the last 3 years), diffuse bronchiectasis, cystic fibrosis, asthma (in clinical history), or any other diagnosed lung diseases (sarcoidosis, pulmonary fibrosis, pneumoconiosis, etc.). Other non-inclusion criteria include exacerbation one month prior to enrolment; absence of a telephone and participation in another clinical or epidemiological study.

Last update : 01/01/2020

SYMFONIE - Longitudinal study of Metabolic Syndrome in France, Observation, Intervention and Epidemiology

Head : Thomas Frédérique

Version 1

267

Last update : 10/20/2017

- Study on physical activity and sports practices in France 2010

Head : Mission des études, de l'observation et des statistiques MEOS

Version 1

268

Last update : 01/01/2020

- Cross-sectional study on nursery schools: individual social characteristics, residential context and prevalence of weight problems in early childhood

Head : Verger Pierre, Unité 379
Guagliardo Valérie , UMR912-SE4S

Version 1